Epilepsy is a common neurological disorder in childhood. Epilepsy is more than twice as common in children as in adults. This statistic reflects the fact that epilepsy frequently remits in adolescence, an outcome which is more commonly noted for certain epilepsy syndromes. However, the underlying mechanism for this marked decrease in seizure susceptibility during adolescence is not known. Now, a study led by SUNY Downstate Medical Center shows that, at the onset of puberty, the emergence of a novel inhibitory brain receptor, reduces seizure-like activity in a mouse model of epilepsy. The team state that their findings may be relevant for remission of childhood epilepsy in adolescence, which is reported for 50–60% of the cases studied. The opensource study is published in the journal Scientific Reports.
Earlier studies from the lab show that expression of α4βδ GABARs increases 4 to 8-fold on the dendrites of CA1 hippocampal pyramidal cells at the onset of puberty in female mice from nearly undetectable levels assessed pre-pubertally. Therefore, the group hypothesized that this increase in GABAergic inhibition during puberty has an inhibitory effect on CA1 hippocampal network activity such as the production of epileptiform bursts. The current study investigates whether pubertal the CA1 hippocampus would generate less seizure-like activity than pre-pubertal hippocampus.
The current study tests the role of α4βδ GABARs receptors in regulating seizure-like discharges in CA1 hippocampus using a high K+ seizure mouse model. The magnitude of the resultant epileptiform activity was assessed using the coastline length measurement, a measure of individual burst intensity, across pubertal stages in mice.
Results shows that seizure-like activity is significantly decreased during the pubertal period due to the increased inhibition provided by α4βδ GABARs which emerge during adolescence in CA1 hippocampus. Data findings show that this decrease in epileptiform activity was not seen in the mouse hippocampus not containing α4βδ GABARs, confirming the role of the α4βδ GABAR in reducing seizure-like activity.
The team surmise that their data suggests that α4βδ GABARs are anti-convulsant during adolescence. For the future, the researchers state that these findings suggest a mechanism for remission of epilepsy in adolescence and also suggest potential new therapies for childhood epilepsy.
Source: SUNY Downstate Medical Center
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.